Drug Trial News

RSS

Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal

Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.

15 Nov 2010

Scios announces results of ASCEND-HF trial for ADHF treatment

Scios Inc. announced today that the landmark investigational study of NATRECOR (nesiritide) for the treatment of acutely decompensated heart failure (ADHF), ASCEND-HF, demonstrated no statistically significant difference from placebo in the co-primary endpoints of dyspnea, measured at six and 24 hours, or in the composite of heart failure re-hospitalizations and death during the first 30 days following treatment.

15 Nov 2010

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010.

15 Nov 2010

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today the results of a Phase 1 study, which reported that PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin (325 mg) and immediate-release omeprazole (40 mg), showed no ex vivo drug-drug interaction with clopidogrel when administered 10 hours apart in healthy patients, based on the study's pre-specified analysis.

15 Nov 2010

Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has announced the completion of enrollment in its Phase IIb imm01 clinical trial of V5 in tuberculosis.

15 Nov 2010

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.

15 Nov 2010

Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting

Dyax Corp. today announced that an abstract featuring KALBITOR (ecallantide) data was accepted for oral presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held November 11-16, at the Phoenix Convention Center in Phoenix, AZ. Two additional abstracts were selected as poster sessions.

15 Nov 2010

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France from November 11 to 13, 2010.

12 Nov 2010

Nile third quarter net loss decreases to $1.8 million

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for therapeutics for cardiovascular disease, today announced its third quarter financial results for 2010.

12 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Results of two pre-specified sub-study analyses of the 18,113 patient RE-LY trial, involving the newly approved oral anticoagulant Pradaxa (dabigatran etexilate mesylate) capsules, will be presented at the American Heart Association's Annual Scientific Sessions on Monday, November 15, 2010.

12 Nov 2010

Inovio to update HVTN 080 Phase I clinical study for HIV at HVTN Conference

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.

12 Nov 2010

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.

12 Nov 2010

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

Acetylon Pharmaceuticals, Inc. today announced that it has been awarded two grants totaling $488,000 under the Qualifying Therapeutic Discovery Project (QTDP) program.

12 Nov 2010

Advaxis receives $244,479 QTDP credit for ADXS11-001 trial

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.

12 Nov 2010

NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010

NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona. The presentation was entitled DAS181 (Fludase), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling.

12 Nov 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

11 Nov 2010

Study investigates long-term outcome of REYATAZ/ritonavir regimens in ARV-experienced patients

Results from a European Observational Study, which included 1,294 antiretroviral (ARV)-experienced patients presented today at the Tenth International Congress on Drug Therapy in HIV Infection (HIV10), demonstrated a low rate of discontinuation and sustained virologic suppression with REYATAZ- (atazanavir)/ritonavir-based regimens over a follow-up period of up to five years.

11 Nov 2010

Drug Trial News

Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal

Scios announces results of ASCEND-HF trial for ADHF treatment

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Nile third quarter net loss decreases to $1.8 million

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Inovio to update HVTN 080 Phase I clinical study for HIV at HVTN Conference

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

Advaxis receives $244,479 QTDP credit for ADXS11-001 trial

NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Study investigates long-term outcome of REYATAZ/ritonavir regimens in ARV-experienced patients

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News